Discover more with  Allergy Therapeutics Annual report and accounts 201 7 of Allergy Therapeutics plc  Strategic Report Mission  Statement To create a sustainable, fast-growing  and profitable global specialty  pharmaceutical business with a  substantial franchise in the allergy  sector by developing innovative,  patented, registered therapies for  both the treatment and prevention  of allergy-related conditions. Strategic Report 01 Highlights 02 What is Immunotherapy? 04 At a Glance 06 Chairman’s Statement 08 Chief Executive Officer’s Review 12 Current Market Overview 14 Opportunities 16 Business Model 18 Strategic Framework 20 Strategy in Action 26 Key Performance Indicators 28 Product Review 32 Research & Development 36 Principal Risks and Uncertainties 39 Financial Review Governance 42 Board of Directors 44 Corporate Governance Allergy Therapeutics is an AIM listed specialty  pharmaceutical group. Allergy Therapeutics is European-based and focused on the  treatment and prevention of allergy with aluminium-free products. © Allergy Therapeutics plc 47 Directors’ Remuneration Report 51 Nominations Committee Report 52 Audit Committee Report 54 Report of the Directors Financial Statements 59 Independent Auditor’s Report to the Members of  Allergy Therapeutics plc 66 Consolidated Income Statement 67 Consolidated Statement of Comprehensive Income 68 Consolidated Balance Sheet 69 Consolidated Statement of Changes in Equity 70 Consolidated Cash Flow Statement 71 Notes to the Financial Statements 109 Company Balance Sheet 110 Statement of Changes in Equity (Company) 111 Notes to Company Balance Sheet 115 Shareholder Information Find this report online at    allergytherapeutics.com 01 Highlights * Percentage based on figures in thousands (2017: £55.545m, 2016: £48.509m) **  Constant currency uses prior year weighted average exchange rates to translate current  year foreign currency denominated revenue to give a year on year comparison excluding  the effects of foreign exchange movements. See table in the Financial Review for an  analysis of revenue on page 39. +72% increase in  operating profit  (pre-R&D)   to £7 .4m  (2016: £4.3m) +15% * revenue growth  at constant  currency  **   to £55.5m   (2016: £48.5m) +32% revenue growth  increase in actual  terms to £64. 1m  (2016: £48.5m) 10% compound  annual growth  in net sales   over 18 years £22.1m Cash at 30 June  (2016: £23.4m) 13% Market share  in the Group’s  main European  markets  (2016: 12%) Financial Operational • Commencement of recruitment for pivotal Phase III Pollinex Quattro Birch trial • US Grass MATA programme proceeding well; safety study successfully completed • First patient recruited for Acarovac MPL Phase I trial in Spain • Positive pre-clinical proof of concept trial data announced for Polyvac Peanut 02 Strategic Report What is  Immunotherapy? Immunotherapy is the practice of  administering gradually increasing   doses of an allergen in order to address  the causes of the symptoms of allergy. It was first carried out almost 100 years  ago and is now in widespread use around  the world..